LONDON, Aug 25, 2021 (GLOBE NEWSWIRE) – Achilles Therapeutics plc (ACHL), a clinical-stage biopharmaceutical company that develops precision T-cell therapies to treat solid tumors, today announced that U.S. patent US 11 098121 and European patent EP3347039B have been granted. The patents cover a method of identifying cancer patients who may respond to a checkpoint inhibitor (CPI) by determining the total number of clonal neoantigens or the ratio of clonal and subclonal neoantigens in patients’ cancer cells. Clonal neoantigens are neoantigens present on all tumor cells and absent from healthy tissue.
Patents are based on data showing that patients with higher numbers of clonal neoantigens respond better to checkpoint inhibitor therapy1. These initial results were confirmed in subsequent studies showing that clonal tumor mutation burden was the strongest predictor of response to IPC in seven different tumor types and three different classes of IPC in over 1,000 patients. processed by IPC.2.
“This is another important step in building our intellectual property position around our precision T-cell therapy platform, supporting our approach to targeting the clonal neoantigens that we identify with our proprietary PELEUS.® bioinformatics platform, ”said Dr Iraj Ali, CEO of Achilles Therapeutics. “This adds to the growing body of data supporting our thesis that clonal neoantigens are the best targets in the treatment of solid tumors. Our technology allows us to prospectively identify and target all of a patient’s unique clonal neoantigens and develop neoantigen-reactive clonal T cells, or cNeT, and ensure that these reactivities are present in the final drug through to our power release test. “
Patents are assigned to Cancer Research Technology and licensed exclusively to Achilles in certain areas. The inventors include three of Achilles’ co-founders, Dr. Sergio Quezada, Scientific Director, Dr. Karl Peggs, Chief Medical Officer, and Professor Charles Swanton, Royal Society Napier Cancer Professor and Chief Clinician of Cancer Research UK, as well as Group Leader at Francis Crick Institute and UCL.
“Achilles continues to advance its development of precision T cell therapies for solid tumor cancers. These patents illustrate the pioneering work Achilles and Cancer Research UK have done in the area of clonal neoantigens, ”said Tony Hickson, business manager of Cancer research in the UK.
1McGranahan et al 2016, Science, https://science.sciencemag.org/content/351/6280/1463
2Litchfield et al 2021, Cell, https://www.cell.com/cell/pdf/S0092-8674(21)00002-7.pdf
About Achilles Therapeutics
Achilles is a clinical-stage biopharmaceutical company developing precision T-cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I / IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses each patient’s DNA sequencing data, along with its proprietary PELEUS ™ bioinformatics platform, to identify patient-specific clonal neoantigens, then develop precision T-cell-based product candidates specifically targeting these patients. clonal neoantigens.
About the Cancer Research UK Business Partnerships team
Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research. Cancer Research UK’s dedicated Business Partnerships team works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with business partners. Cancer Research UK’s business activity is conducted through Cancer Research Technology Ltd., a wholly owned subsidiary of Cancer Research UK. It is the legal entity that pursues research on drug discovery within the framework of thematic alliance partnerships and offers various commercial partnership agreements.
This press release contains express or implied forward-looking statements which are based on the beliefs and assumptions of our management and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our results, performances or achievements are materially different from the future results, performances or achievements expressed or implied by these forward-looking statements. The forward-looking statements contained in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will change our perspective. However, although we may choose to update these forward-looking statements at any time in the future, we currently have no intention of doing so, except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our opinions as of a date subsequent to the date of this press release.
More information :
Lee M. Stern – Vice-President, IR and External Communications
+1 (332) 373-2634
Strategic communication of the Consilium
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
+44 (0) 203 709 5000